MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » FDA grants de novo clearance to AI Biomed, FluoOptics parathyroid tissue detection devices

FDA grants de novo clearance to AI Biomed, FluoOptics parathyroid tissue detection devices

By

FDA

The FDA today granted de novo clearance to parathyroid tissue detection devices from both Fluoptics and AI Biomed.

The systems are intended to provide the real-time location of parathyroid tissue during surgical procedures including thyroidectomy and parathyroidectomy, the federal watchdog said.

FluOptics won approval for its Fluobeam 800 clinic imaging device which can be used as a companion to assist in locating parathyroid tissue during surgery, the FDA said. Parathyroid tissue emits a fluorescent glow when exposed to the Fluobeam’s light source, which eliminates the need for a contrast agent.

The system previously won clearance as an imaging system to capture and view fluorescent images for visually assessing blood flow as an adjunctive method of evaluating tissue perfusion, the agency said.

Approval came based on data from five peer-reviewed published studies, including a trial that compared postoperative hypocalcemia (PH) rates post-removal of parathyroid tissue. Results indicated that in 93 patients who underwent procedures with the device, 5% experienced fluctuating PH levels following surgery, lower than the 21% reported on 153 patients who underwent surgery without the device, the agency said.

AI Biomed won clearance for its Parathyroid Detection PTeye system, which is intended to aid in detecting parathyroid tissue by using a probe that emits fluorescent light. The system provides both audio and visual displays to indicate the presence of parathyroid tissue, the FDA said.

The system won approval based on data from a single-blinded study of 81 patients treated with the device, with data indicating that the PTeye system could correctly identify parathyroid tissue as compared to histology 93% of the time, and the absence of such tissue as compared to intraoperative expert visualization 97% of the time. The overall accuracy of the device was reported as 96%, the FDA reported.

“For some patients with parathyroid disease, treatment may mean a surgical procedure. Real-time identification of parathyroid tissue during surgery can provide surgeons with valuable information to help preserve healthy tissue or to remove diseased tissue,” FDA Center for Devices and Radiological Health Division of Surgical Devices director Dr. Binita Ashar said in a press release.

In case you missed it

RSS From Medical Design & Outsourcing

  • Versapor® RC Membranes: The next generation of venting materials
    As the world leader in the design and production of membranes, filtration devices, and separation systems, Pall Corporation supplies products to nearly every industry in the world. Founded in 1946, Pall Corporation has set the standard for filtration solutions for 75 years and counting. Our customers have relied on us for their most sophisticated applications… […]
  • Tips to help bring your medical device from mind to market
    By Bret Ludwig, Ph.D. Senior Product Development Specialist, 3M Medical Materials & Technologies Great medical devices start with an idea—a spark. And from there, it might move to the back of a napkin or a notepad. But as development continues, the process can get trickier and more complex. In fact, turning an idea into a… […]
  • Salt baths increase stability in the medical device tempering process
    Calibration baths, like salt baths, were originally for calibrating temperature assets. But there’s another use for them: manufacturing Nitinol medical devices. Travis Porter, Fluke Calibration Nitinol is a nickel-titanium alloy that exhibits both thermal shape memory behavior and super-elasticity. It’s a great metal to use in medical devices because it’s possible to set the wire… […]
  • Traco Power announces new TMW 24 and TMW 36 series
    Traco Power (San Jose, Calif.) recently announced the company’s new TMW series of 24- and 36-W power supplies. The new power supplies are IP68 rated and fully encapsulated — with flexible options for PCB or chassis mounting for the medical and industrial markets. The TMW Series were also designed for flush box-mounting to support IoT… […]
  • Protolabs reports mixed-bag results for Q2
    Protolabs (NYSE: PRLB) posted second-quarter earnings today that missed the consensus forecast on Wall Street, though the company beat on revenue. The Maple Plain, Minn–based digital manufacturing outsourcer — which serves medtech and a host of other industries — reported profits of $12.9 million, or 47¢ per share, on sales of $123.0 million for the… […]
  • Integer beats The Street in Q2, boosts sales outlook
    Integer Holdings (NYSE:ITGR) posted second-quarter results today that beat the consensus forecast on Wall Street — boosting its 2021 sales outlook amid continued recovery from the COVID-19 pandemic. The Plano, Texas–based medical device contract manufacturing giant reported profits of $29.4 million, or 89¢ per share, on sales of $312.0 million for the three months ended… […]
  • Keep the end in mind when choosing a medtech partner
    There are five general categories of medtech vendor partners. If the end is apparent in the beginning, the correct type of partner will be clearer. Jim Reed, Minnetronix Medical Stephen Covey gave the business world this mantra in one of his bestsellers: “Start with the end in mind.” Whether they didn’t read the book or… […]
  • Orthofix launches Fiberfuse Strip bone graft
    Orthofix (NSDQ:OFIX) today announced that it has launched its FiberFuse Strip bone graft in the U.S. Lewisville, Texas–based Orthofix designed the FiberFuse Strip to be a preformed bone-graft strip for posterior cervical, posterior lumbar and degenerative spinal procedures. FiberFuse Strip is 100% bone and has a unique mixture of mineralized cancellous and demineralized cortical bone with… […]
  • Thermo Fisher Scientific beats The Street in Q2 results
    Thermo Fisher Scientific (NYSE:TMO) today posted second-quarter results that beat the overall consensus on Wall Street. The Waltham, Mass.–based company reported profits of $1.8 billion, or $4.61 per share, on sales of $9.3 billion for the three months ended July 1, 2021, for a bottom-line gain of 58.1% on sales growth of 34.1% compared with… […]
  • Choosing the Right Rubber Material and Process for Your Medical Parts
    When it’s time to design and develop a new medical device that calls for an elastomer component, there are a number of material options and manufacturing processes to consider. The long list of material properties impacting performance includes your prospective polymer’s end-use environment, chemical compatibility, hardness, compression set, tensile properties and manufacturability — to name… […]
  • 3M’s healthcare segment registers growth in Street-beating Q2
    3M (NYSE:MMM) reported second-quarter results that beat the consensus forecast — with the company’s healthcare segment showing especially robust growth. The St. Paul, Minn.–based company posted profits of $1.5 billion, or $2.59 per share, on sales of $9 billion for the three months ended June 30, 2021, for a 16.7% bottom-line gain on sales growth of… […]